Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: Population based cohort study

BMJ (Online)

Volumn 360, Issue , 2018, Pages

  Patorno, Elisabetta ^a   Goldfine, Allison B ^b   Schneeweiss, Sebastian ^a   Everett, Brendan M ^a   Glynn, Robert J ^a   Liu, Jun ^a   Kim, Seoyoung C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; HEMOGLOBIN A1C; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; INFORMATION PROCESSING; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK FACTOR; AGED; AGONISTS; BIOASSAY; MIDDLE AGED; UNITED STATES;

ADULT; AGED; CANAGLIFLOZIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDPOINT DETERMINATION; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; UNITED STATES;

EID: 85041737787     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.k119     Document Type: Article

References (29)

1. MacDonald MR, Petrie MC, Varyani F, et al, CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008; 29: 1377-85. doi: 10. 1093/eurheartj/ehn153
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53. doi: 10. 1016/S0140-6736(98)07019-6
3. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59. doi: 10. 1056/NEJMoa0802743
4. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71. doi: 10. 1056/NEJMoa072761
5. Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2017; 24: 73-9. doi: 10. 1097/MED. 0000000000000311
6. Häring HU, Merker L, Seewaldt-Becker E, et al, EMPA-REG METSU Trial Investigators. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, doubleblind, placebo-controlled trial. Diabetes Care 2013; 36: 3396-404. doi: 10. 2337/dc12-2673
7. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 2016; 18: 783-94. doi: 10. 1111/dom. 12670
8. Zinman B, Wanner C, Lachin JM, et al, EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-28. doi: 10. 1056/NEJMoa1504720
9. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377: 644-657. doi: 10. 1056/NEJMoa1611925.
10. Kosiborod M, Cavender MA, Fu AZ, et al. Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVDREAL Study. Circulation 2017; 136: 249-259. doi: 10. 1161/CIRCULATIONAHA. 117. 029190.
11. Persson F, Nyström T, Jørgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab 2017; 1-8. doi: 10. 1111/dom. 13077
12. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 323-37. doi: 10. 1016/j. jclinepi. 2004. 10. 012
13. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004; 148: 99-104. doi: 10. 1016/j. ahj. 2004. 02. 013
14. Wahl PM, Rodgers K, Schneeweiss S, et al. Validation of claimsbased diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf 2010; 19: 596-603. doi: 10. 1002/pds. 1924
15. Tirschwell DL, Longstreth WT Jr. Validating administrative data in stroke research. Stroke 2002; 33: 2465-70. doi: 10. 1161/01. STR. 0000032240. 28636. BD
16. Saczynski JS, Andrade SE, Harrold LR, et al. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf 2012; 21(Suppl 1): 129-40. doi: 10. 1002/pds. 2313
17. Social Security's Death Master File. Accessed February 20, 2017, at https://www. ssa. gov/dataexchange/request-dmf. html.
18. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-63. doi: 10. 7326/0003-4819-127-8-Part-2-199710151-00064
19. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011; 10: 150-61. doi: 10. 1002/pst. 433
20. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28: 3083-107. doi: 10. 1002/sim. 3697
21. Kleinbaum DG, Klein M. Evaluating the Proportional Hazards Assumption. In: Gail MKK, Samet J, Tsiatis A, Wong W, eds. A Self-Learning Text. 3rd ed. Springer, 2012. doi: 10. 1007/978-1-4419-6646-9-4.
22. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010; 19: 858-68. doi: 10. 1002/pds. 1926
23. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 2011; 64: 749-59. doi: 10. 1016/j. jclinepi. 2010. 10. 004
24. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004; 141: 929-37. doi: 10. 7326/0003-4819-141-12-200412210-00009
25. Everett BM, Hiatt WR. Finding Efficacy in a Safety Trial: Empagliflozin and Cardiovascular Death. Circulation 2016; 134: 773-5. doi: 10. 1161/CIRCULATIONAHA. 116. 024512
26. Guidance for Industry. Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes 2008. (Accessed February 16, 2017, at https://www. fda. gov/downloads/Drugs/./Guidances/ucm071627. pdf.)
27. Important notice: change in public death master file records. 2011. (Accessed February 20, 2017, at https://classic. ntis. gov/assets/pdf/import-change-dmf. pdf.)
28. Patorno E, Gopalakrishnan C, Franklin JM, Brodovicz KG, Masso-Gonzalez E, Bartels DB, Liu J, Schneeweiss S. Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes Obes Metab. 2017doi: 10. 1111/dom. 13184
29. Patorno E, Goldfine AB, Schneeweiss S, Glynn RJ, Liu J, Kim SC. Cardiovascular Safety of Canagliflozin Vs. Other Antidiabetic Agents in Routine Care. Presented at: 77th Scientific Sessions of the American-Diabetes-Association; June 09-13, 2017; San Diego, USA.